What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹249 Cr over the trailing twelve months.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from PARNAX LAB LTD.'s filed financials and exchange disclosures
PARNAX LAB LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol PARNAXLAB.
Yes. Over the trailing twelve months PARNAX LAB LTD. reported a net profit of ₹12 Cr on revenue of ₹249 Cr.
Not in the latest reported year — PARNAX LAB LTD.'s dividend payout for FY26 was nil.
No. Debt stands at 0.78× equity, and it carries net debt of ₹74 Cr. That is lower than 11% of its 171 Pharmaceuticals peers.
On trailing P/E, PARNAX LAB LTD. ranks 32 of 169 in Pharmaceuticals — cheaper than 82% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
Every NSE and BSE filing by PARNAX LAB LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
